webinar series
ACC.26 Highlights for the Cardiology Pharmacist
Key Learning Objectives
After watching this interview, learners will be able to:
· Identify the three ACC.26 late-breaking trials with the most direct impact on cardiovascular pharmacotherapy practice.
· Interpret the clinical implications of CHAMPION AF, SPIRIT HF, and VESALIUS-CV from a clinical pharmacist's perspective.
· Translate the latest trial evidence into practical, day-to-day prescribing and medication optimisation decisions.
· Recognise the expanding role of the cardiology pharmacist within multidisciplinary cardiovascular care teams.
· Apply evidence-based recommendations to improve patient outcomes across heart failure, atrial fibrillation, and lipid management.
Who Should Attend
This interview is intended for cardiology pharmacists, clinical pharmacists, cardiologists, internists, advanced practice providers, nurses, and allied healthcare professionals involved in the pharmacological management of cardiovascular disease — particularly those interested in evidence-based, multidisciplinary cardiovascular care.
Production Credits
Produced in collaboration with Radcliffe Cardiology and ISCP. Published: 8 April 2026.
restricted content
ISCP Members Only
Access to the e-Learning and Experts sections is available to ISCP Members only. Already a Member? Log in Not yet a Member? Visit our Registration page for details of how to join the ISCP and learn more about the benefits of being a part.